In vivo experiments suggest an important role for APRIL in the long-term survival of plasma cells in the bone marrow.

[7] However, APRIL-deficient mice have also been reported to possess a reduced ability to support plasma cell survival.

[9] Three alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.

[12] At least one anti-APRIL monoclonal antibody has been announced to enter phase I clinical trials for multiple myeloma.

[13] This article incorporates text from the United States National Library of Medicine, which is in the public domain.